Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
This compound is not FDA approved
Stein IF, Leventhal ML
Elashoff (79) also suggested that, compared with other common hypoglycemic drugs, GLP-1RA may increase the risk of chronic pancreatitis and then change the levels of cellular inflammatory factors and reactive oxygen species, thus increasing the risk of pancreatic cancer
This may have been because those with lower BMIs may have had normalisation of their obesity and thus further weight loss was not physiologically possible
They may want to discuss the available options with their clinician. Future research may focus on comparing the effectiveness of different treatments after GLP-1 discontinuation
